<DOC>
	<DOC>NCT00430144</DOC>
	<brief_summary>-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix</brief_summary>
	<brief_title>Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix</brief_title>
	<detailed_description>- list item one, to evaluate toxicities of Belotecan - list item two, to evaluate duration of primary response for responding patients - list item three, to evaluate time to disease progression - list item four, to evaluate progression free survival and overall survival.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirmed, patients with recurrent uterine cervical carcinoma who were unsuitable candidates for curative treatment with surgery and/or radiotherapy. One of the following histologic types Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Clinically measurable disease Performance status of 0, 1, 2 on the ECOG criteria Histology of neuroendocrine tumors Patient previously treated with topoisomeraseI inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>